Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
10x Genomics, a leader in life sciences, announced its participation in a fireside chat at the BofA Securities 2023 Healthcare Conference on May 10, 2023, at 2:20 p.m. Pacific Time. The event will focus on advancing human health through innovative biological solutions.
Investors can access a live webcast of the chat via the company's website, with an archive available for replay for at least 45 days. 10x Genomics specializes in integrated solutions that include instruments, consumables, and software for biological analysis. The company has a strong presence in top research institutions and pharmaceutical companies, cited in over 4,500 research papers.